Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Surgery Partners (SGRY) EBITDA Margin: 2013-2024

Historic EBITDA Margin for Surgery Partners (SGRY) over the last 11 years, with FY2024 value amounting to 15.85%.

  • Surgery Partners' EBITDA Margin rose 49600.0% to 12.87% in Q3 2025 from the same period last year, while for Sep 2025 it was 12.36%, marking a year-over-year increase of 15400.0%. This contributed to the annual value of 15.85% for FY2024, which is 2200.0% down from last year.
  • Latest data reveals that Surgery Partners reported EBITDA Margin of 15.85% as of FY2024, which was down 2200.0% from 16.07% recorded in FY2023.
  • Surgery Partners' EBITDA Margin's 5-year high stood at 18.01% during FY2022, with a 5-year trough of 14.7% in FY2020.
  • Its 5-year average for EBITDA Margin is 16.49%, with a median of 16.07% in 2023.
  • In the last 5 years, Surgery Partners' EBITDA Margin crashed by -21000bps in 2020 and then soared by 31200bps in 2021.
  • Surgery Partners' EBITDA Margin (Annual) stood at 14.7% in 2020, then rose by 21bps to 17.83% in 2021, then increased by 1bps to 18.01% in 2022, then fell by -11bps to 16.07% in 2023, then dropped by -1bps to 15.85% in 2024.
  • Its EBITDA Margin stands at 15.85% for FY2024, versus 16.07% for FY2023 and 18.01% for FY2022.